Investor Presentaiton

ECLIPSE trial demonstrated efficacy 83% CRC Sensitivity 90% Specificity INVESTOR 20 DAY 23 ● 100% sensitivity stage II and stage III/IV • 81% CRC sensitivity at stage | - ||| • 55% sensitivity stage I ● 13% advanced adenoma sensitivity GUARDANT™ Source: Chung, D., Gray, D. M., Greenson, J., Gupta, S., Eagle, C., Hu, S., Talasaz, A., Issaka, R. B., Singh, H., Sinicrope, F. A., & Grady, W. (2023). 913e Clinical validation of a cell-free DNA blood-based test for colorectal cancer screening in an average risk population. Gastroenterology, 164(6), S. https://doi.org/10.1016/S0016-5085(23)04760-1 105

View entire presentation